Zavzpret (Zavegepant HCl) Patent Expiration, LOE Window & CMS Spending

Zavzpret (Zavegepant HCl) by Pfizer: FDA Orange Book core substance LOE 2034-06-26, 0 AB generics, $15.4M 2024 CMS Part D & Medicaid spend, and $1,100 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN216386 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-06-26
Last Listed Patent or Exclusivity Date2034-06-26
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$15.4M
2024 Medicare Part D Spend$8.9M
2024 Medicaid Spend$6.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,100 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.